InMed Pharmaceuticals Inc. (INM) Institutional Ownership

Ownership Summary

InMed Pharmaceuticals Inc. (NASDAQ:INM) currently has 2 active institutional owners and shareholders as of today (December 2025), that have filed 13F forms with the Securities Exchange Commission (SEC).

• Institutional ownership in InMed Pharmaceuticals edged down to 0.1% in December 2025, compared to 23.8% in September 2025.
• On a quarter-over-quarter basis, institutional holdings shifted by 125.67%, with a year-over-year a decrease of 66.67% in the count of filers.
• Of these 2 institutional investors, 1 increased their holdings in InMed Pharmaceuticals, while 0 of them reduced positions, and 1 investors maintained their exposure.
• This class of investors increased its holdings in InMed Pharmaceuticals to 677 shares for the 13F-cycle ending December 2025, up by 377 shares quarter on quarter, and down 48.22K shares year over year.
• UBS Group AG's holding of 377 shares as of December 31, 2025 makes it the primary institutional investor in InMed Pharmaceuticals, owning 0.03% of the stock.
• Among the most significant buyers of InMed Pharmaceuticals during December 2025 were UBS Group AG (377).
• The top 2 institutional holders of InMed Pharmaceuticals for the quarter ending December 2025 included UBS Group AG (377), SBI Securities Co., Ltd. (300).